Intellicell Biosciences Inc (fka SVFC)

[Toeinmouth]

IntelliCell BioSciences Has Received Its Hong Kong Patent Application Notice for ULTRASONIC CAVITATION

Date : 04/02/2014 @ 11:57AM
Source : Marketwired
Stock : Intellicell Biosciences, Inc. (PL) (SVFC)
Quote : 0.0041 0.0 (0.00%) @ 4:37PM

IntelliCell BioSciences Has Received Its Hong Kong Patent Application Notice for ULTRASONIC CAVITATION

Intellicell Biosciences, Inc. (PL) (USOTC:SVFC)
Historical Stock Chart

1 Month : From Apr 2014 to May 2014
Click Here for more Intellicell Biosciences, Inc. (PL) Charts. IntelliCell BioSciences Has Received Its Hong Kong Patent Application Notice for ULTRASONIC CAVITATION

NEW YORK, NY--(Marketwired - Apr 2, 2014) - IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular fraction cells (SVFCs) derived from the blood vessels found in adipose tissue, has received notice of publication for its technology patent in Hong Kong for ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USE THEREOF.
HK Patent Application No 13113908.9

IntelliCell's Chief Executive Officer, Dr. Victor, remarked, "This is wonderful news in that we are expanding our international patent portfolio to further protect our patent around the world. And I believe that we are now in the phase of our international patent process to reach out and seek international partners to whom we would license our technology and cellular labs and start generating international revenues."

About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.


Contact:
IntelliCell BioSciences, Inc.
Investor Relations
Anna Rhodes
Email Contact
(646

http://ih.advfn.com/p.php?pid=nmona&article=61697331